Skip to main content

Calidi Biotherapeutics, Inc.

CLDI
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001855485

No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.

Other share classesCLDWW

Q2 2022 vs. Q1 2022

How the institutions holding Calidi Biotherapeutics, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of CLDI: Q1 2022 compared with Q2 2022
MeasureQ1 2022Q2 2022Change
Holders4042+2
Shares20.5M20.8M+299.9K (+1.5%)
Value$202.4M$205.5M+$3.09M (+1.5%)

New holders (5)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to CLDI in Q2 2022
InstitutionSharesValue% of portfolio
Parallax Volatility Advisers, L.P.254,044$2.52M0.01%
Elequin Capital LP40,000$398.0K0.09%
Cohen & Co Financial Management, LLC31,767$3.00K0.00%
Clear Street LLC100$1.00K0.00%
Magnetar Financial LLC63,132$00.00%

Sold out (3)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of CLDI in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Beryl Capital Management LLC1,159,998$11.5M
Pinz Capital Management, LP57,000$564.0K
Cohanzick Management, LLC2,550$25.0K